COMP <GO>
QNRX vs MCRB // EV/EBITDA & P/E VALUATION
Quoin Pharmaceuticals Ltd. (NASDAQ) VS. Seres Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: QNRX 2
— MCRB 1
■ METRIC PARITY
LAST: $4.15 (+0.97%) • MKT CAP: $19.9M
valuation
—
LAST: $1.95 (+8.94%) • MKT CAP: $19.6M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (QNRX VS. MCRB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | QNRX | MCRB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 4.42% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 68.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 5/9 | -3.00 | MCRB | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.3 | 20.9 | +28.44 | QNRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $19.9M | $19.6M | $349.9K | QNRX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | QNRX REV | MCRB REV | QNRX GROSS % | MCRB GROSS % | QNRX FCF | MCRB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $789.0K | — | — | -$13.5M | $865.0K |
| FY 2024 | $0 | $0 | — | — | -$7.9M | -$149.0M |
| FY 2023 | $0 | $0 | — | — | -$7.9M | -$117.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
QNRX // BETA —
MCRB // BETA —